Optive® OMEGA™ UD
OPTIVE OMEGA™ UD is a unique combination formula containing linseed
oil, a source of Omega-3, for rapid and long-lasting
relief of lipid-deficient dry eye symptoms.1,2
OPTIVE OMEGA™ UD helps protect against tear evaporation by providing
lubrication and moisture to the eye surface, supporting
tear film stability.1
OPTIVE OMEGA™ UD supports hydration and helps maintain healthy ocular
surface cells by restoring osmotic balance and
protecting natural tears through lipid enhancement.1,3
Preservative-free, convenient single-use vials.
No shaking required prior to use.4
Innovative technology
Introducing innovative technology by combining linseed oil, a source
of Omega-3, CMC, and osmoprotectants into one
drop.
OPTIVE OMEGA™ UD provides rapid and long-lasting relief of symptoms
associated with lipid-deficient Dry Eye Disease.1,2
Castor and Linseed oils: 3-5
Stabilizes the lipid layer
Protects natural tears
Anti-inflammatory effect in DED
Carboxymethylcellulose (CMC): 6-8
Improved comfort
Effective lubrication
Stays on the eye longer
Osmoprotectants 9-11
Provides hydration
Protects against hyperosmotic stress
Restores osmotic balance
Instillation
To apply the eye drops, first wash your hands, then twist the top off the unit dose vial. Place 1 or 2 drops of OPTIVE OMEGA™ UD in the affected eye(s) as needed.
Step 1
Tilt your head back, look upwards, and gently pull down your lower eyelid to create a small gap.
Step 2
Twist off the end of the vial and hold upside
down, allowing each drop to fall into the eye
Avoid touching the surface of the eye or eyelids
with the applicator tip
Use one or two drops per eye as needed
Step 3
Close the eye for two or three seconds to help spread OPTIVE OMEGA™ UD evenly over the surface of the eye.
Ingredients
OPTIVE OMEGA™ UD is supplied in foil wrapped pouches. Each vial contains 0,4 ml of solution.
Each ml contains:
Sodium hyaluronate 0.5%
Glycerine 1,0 %
Linseed and castor oils
Polysorbate 80 0,5%
PRESERVATIVE-FREE
Precautions
- - Do not use if allergic to any of the ingredients
- - Do not swallow solution
- - To avoid contamination or possible eye injury, do not touch vial tip on any surface, and avoid direct contact with the eye
- - Do not use after expiry date marked on the product
- - Keep out of the reach of children
- - Store at room temperature
- - Allow 5 minutes between the administrations of ophthalmic product
- - Do not use the unit dose vial or product packaging if damaged
- - Do not use if solution changes colour
- - Keep away from sunlight
- - Use vial once and discard
Add-on treatment
Higher-viscosity OPTIVE® GEL DROPS are an effective add-on treatment to OPTIVE PLUS™ , providing long-lasting relief both during the day and at night.
OPTIVE OMEGA™ Unit Dose Eye Drops: Contains
carboxymethylcellulose sodium 5 mg/ml, glycerine 10 mg/ml,
polysorbate 80 5 mg/ml, linseed oil, and castor oil.
OPTIVE PLUS™ Eye Drops: Contains
carboxymethylcellulose sodium 5 mg/ml, glycerine 10 mg/ml, castor
oil 2,5 mg/ml, and polysorbate 80 5 mg/ml.
OPTIVE FUSION™ Eye Drops: Contains sodium
hyaluronate 1 mg/ml, carboxymethylcellulose sodium 5 mg/ml, and
glycerine 9 mg/ml.
OPTIVE® Lubricant Eye Gel Drops: Contains
carboxymethylcellulose sodium 10 mg/ml and glycerine 9 mg/ml.
For full prescribing information, refer to the
Instructions for Use.
Allergan Pharmaceuticals (Pty) Ltd, PO Box 6024, Halfway House,
1685, South Africa (Co. Reg. no. 1984/005576/07)
Telephone: +27 (0) 11 545 6600, Facsimile: +27 (0) 11 315 6008
www.allergan.co.za
© 2021. ®/™ Registered Trademark/Trademark of Allergan, Inc. Date
of preparation: June 2021. SA-OPT-2150062
Clinical References
1. OPTIVE OMEGA™ UD DFU.
2. Fogt JS, et al. Clin Ophthalmol 2019;13:2553-2561.
3. Downie LE, et al. Ocul Surf 2020;18:148-157
4. Beard BJ, et al. Abstract 115550, Presented at Am Acad Omptometry. 2011
5. Rashid S, et al. Arch Ophthalmol 2008;126(2):219-225
6. White CJ, et al. Contact Lens & Anterior Eye 2014;37:81-91.
7. Garret Q, et al. Invest Ophthalmol Vis Sci 2007;48:1559-1567.
8. Monaco G, et al. Eur J Ophthalmol 2011;21(3):243-250.
9. Foulks GN. Drugs Aging 2008;25(2):105-118.
10. Mager WH, Siderius M. FEMS Yeast Research 2002;2:251-257
11. Yancey PH. J Exp Biol 2005;208:2819-2830